Clinical course of XXXX -induced @entity8 in @entity1 with @entity309 .

@entity1 @entity644 @entity8 @entity38974 @entity177 @entity309 @entity703
BACKGROUND: @entity38974 , a disease-modifying antirheumatic drug widely prescribed in Japan, is reported to be a cause of @entity644 . However, to date, the clinical course of the @entity8 associated with the use of @entity38974 has not been described in detail. METHODS: We analyzed renal biopsy findings from 10 @entity1 with @entity309 and concomitant @entity38974 -induced @entity8 . Each @entity1 was followed up until @entity644 had resolved. RESULTS: @entity644 appeared 2-11 months after the initiation of the treatment with @entity38974 . Nine @entity1 , who stopped @entity38974 treatment immediately (within 3 months) after the onset of @entity644 , were diagnosed as having stage I @entity8 . Only one @entity1 , who used @entity38974 for 9.5 months after the onset of @entity644 , was diagnosed as having @entity703 . In all @entity1 with stage I @entity8 , the @entity644 disappeared within 7 months after they stopped @entity38974 treatment. On the other hand, in the @entity1 with @entity703 , the @entity644 persisted for 14 months after the use of @entity38974 was stopped. In all the @entity1 , the @entity644 resolved completely without @entity177 . None of the @entity1 has experienced recurrence of @entity644 . CONCLUSIONS: In @entity1 with @entity644 induced by treatment with @entity38974 , @entity8 is the most common disorder. Immediate withdrawal of @entity38974 results in prompt and complete resolution of @entity644 without @entity177 . @entity38974 , a disease-modifying antirheumatic drug widely prescribed in Japan, is reported to be a cause of @entity644 . However, to date, the clinical course of the @entity8 associated with the use of @entity38974 has not been described in detail.
